Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia
Sponsored by Mohammed Abd El Mawgoud Amer
About this trial
Last updated 3 years ago
Study ID
Male Androgenic Alopecia
Status
Recruiting
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 45 Years
All
Trial Timing
Ended 3 years ago
What is this trial about?
Androgenetic alopecia (AGA) is hair loss with specific clinical pattern, It Is characterized
by follicular miniaturization, which occurs due to systemic androgens and genetic factors.
Prevalence differs according to ethnic groups. It is more common and more severe in white men
than in Asian and black men. The incidence increases with age. According to Hamilton's study,
the prevalence is 30% in men at the age of 30, and 50% in the age of 50. Generally, the age
of onset is the 3rd and 4th decade.
What are the participation requirements?
Inclusion Criteria
- Subjects clinically and dermoscopic diagnosed with AGA.
- Age ranges from 18 to 45 years old.
- Males
- Willingness to provide pictures and follow-up studies.
Exclusion Criteria
- Patients who received any topical or systemic treatment for AGA during the last 6 months,
- Patients who had other types of alopecia such as alopecia areata, alopecia totalis, telogen effluvium, anagen effluvium, and acquired cicatricial alopecia.
- Patients with anemia, thyroid disease, and vitamin D deficiency,
- Any autoimmune disease or chronic debilitating disease (chronic renal failure, congestive heart failure, hepatic patients, cancer patients).
Locations
Location
Status
Recruiting